Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578-03 neoadjuvant therapy after chemoradiation in resectable advanced rectal cancer
jRCT2051200096Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ONO-4578 and nivolumab in rectal adenocarcinoma (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability of ONO-4578 and ONO-4578 + ONO-4538 neoadjuvant therapy. Started Jan 2021; status: completed.
02
Drugs
ONO-4578nivolumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2051200096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200096.